Form 8-K · Current Report · Filed 2024-11-06
Revolution Medicines Announces Third Quarter 2024 Financial Results and Corporate Updates
Revolution Medicines, Inc. announced its financial results for the quarter ended September 30, 2024, reporting a cash position of $1.55 billion. The company incurred a net loss of $156.3 million for the quarter. The company is progressing with clinical trials for its RAS(ON) inhibitors, including RMC-6236 in Phase 3 and RMC-9805 in early-stage trials. Financial results indicate higher R&D expenses due to clinical trial activities. Revolution Medicines expects its current cash reserves to fund operations into 2027.
- Filer
- Revolution Medicines Inc. RVMD · NASDAQ
- Filed
- Accession
- 0000950170-24-122266
- CIK
- 0001628171
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$56.75
Next session
+4.1%
Since filing
+230.4%
Latest close
$187.53
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVMD reporting the same item, with the next session's move:
Exhibits (1)
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Never miss another RVMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.